Absence of BCS–BEC crossover in FeSe_(0.45)Te_(0.55) superconductor

In iron-based superconductor Fe(Se,Te), a flat band-like feature near the Fermi level was observed around the Brillouin zone center in the superconducting state. It is under debate whether this is the evidence on the presence of the BCS–BEC[Bardeen–Cooper–Schrieffer(BCS), Bose–Einstein condensation(BEC)] crossover in the superconductor. High-resolution laser-based angle-resolved photoemission measurements are carried out on high quality single crystals of FeSe_(0.45)Te_(0.55) superconductor to address the issue. By employing different polarization geometries, we have resolved and isolated the dyz band and the topological surface band, making it possible to study their superconducting behaviors separately. The dyz band alone does not form a flat band-like feature in the superconducting state and the measured dispersion can be well described by the BCS picture. We find that the flat band-like feature is formed from the combination of the dyz band and the topological surface state band in the superconducting state. These results reveal the origin of the flat band-like feature and rule out the presence of BCS-BEC crossover in Fe(Se,Te) superconductor.

基于BCS-KL方法的地层边界不确定性研究

在工程建设中获取的现场钻孔数据有限,利用钻孔数据解释地下地层不可避免地存在不确定性,进而影响桩基础等工程设计的可靠性。对此,提出了从有限钻孔数据中量化地层边界不确定性的方法,并研究地层边界不确定性对单桩竖向承载力特征值的影响。首先依据钻孔数据,通过贝叶斯压缩采样-KL展开(BCS-KL)方法重建地层边界,并生成大量随机场数据量化地层边界的统计不确定性;然后依据地层边界数据,对单桩竖向承载力特征值进行不确定性分析。分析结果表明:BCS-KL方法生成的大量随机场数据能很好地表征地层边界的不确定性;在钻孔间距较大时,单桩竖向承载力特征值在95%置信区间内相差4 660.88 kN,差距较大。通过BSC-KL方法科学评估地层边界不确定性对单桩竖向承载力的影响,对确保工程设计可靠性具有重要意义。

Subconjunctival hemorrhage after wet cupping therapy: a case report

Introduction:Cupping therapy is an integrative and complementary medicine therapy that practiced worldwide by several civilizations for thousands of years.Cupping therapy is reported to be a relatively safe practice especially if performed by qualified therapists.Subconjunctival hemorrhage(SCH)is a common cause of eye redness and can be classified into traumatic and spontaneous.Case presentation:This case report discussed an adverse event related to wet cupping therapy.The patient developed SCH one day after performing cupping therapy.He was completely recovered after 2 weeks.This case report should increase the knowledge of cupping therapists regarding increasing safety of patient when performing wet cupping therapy on specific body parts especially,head,neck and cervical areas.Furthermore,it highlighted the importance of conducting research regarding the mechanical and physiological effects of cupping therapy.Conclusion:Adverse events related to cupping therapy should be reported with every patient.Cupping therapists should be aware of this possible mild adverse event.To the best of our knowledge,this is the first published adult case of SCH related to wet cupping therapy session.More studies are critically needed for evaluation of cupping therapy effects and adverse events especially when performed on head and neck.

铜增韧Mo_(2)BC陶瓷的力学性能和摩擦学性能

采用快速热压反应烧结法制备高强韧Mo_(2)BC/Cu陶瓷基复合材料。研究铜含量对Mo_(2)BC/Cu复合材料的微观组织、力学性能和摩擦学性能的影响,并对其增韧机制和磨损机理进行分析。研究结果表明:Cu均匀地分散在Mo_(2)BC基体中,具有细化晶粒的作用。Mo_(2)BC/Cu复合材料中铜可以添加的最大质量分数为7.5%。随着铜含量的增加,Mo_(2)BC/Cu复合材料的弯曲强度和断裂韧性增加。当Cu质量分数为7.5%时,复合材料的弯曲强度和断裂韧性最高,分别为625.1 MPa和7.4 MPa·m^(1/2),与Mo_(2)BC陶瓷相比,分别提高了24%和62%,其主要的增韧机制为铜的塑性变形、晶粒拔出、桥接效应和裂纹的偏转。此外,铜的添加还可以明显提高Mo_(2)BC/Cu复合材料的摩擦磨损性能。当Cu质量分数为2.5%时,复合材料的摩擦因数可低至0.36,磨损量最小,耐磨性最优,其主要的磨损机制为轻微的二体磨粒磨损和氧化磨损。

基于新载体的BC-L-83碳三加氢催化剂的开发及工业应用

针对国产碳三液相加氢BC-L-83催化剂的特点和不足,开发了基于新载体的BC-L-83碳三液相选择加氢催化剂,考察了新BC-L-83催化剂在工业乙烯装置上的长周期应用情况。工业应用结果表明,新BC-L-83催化剂在国内1.2 Mt/a乙烯装置中首次稳定运行22个月以上,催化剂活性高,抗波动性能好,丙烯平均选择性超过73%,更好地满足了工业乙烯装置脱除碳三馏分中的丙炔、丙二烯和增产丙烯的要求,具有明显的技术和成本优势。

BC120全自动血培养系统作为药品无菌检查替代方法的可行性研究

目的:评价基于呼吸信号检测原理的BC120全自动血培养系统在特定注射剂产品中作为替代方法开展无菌检查的可行性。方法:收集2种不同类型的无菌制剂,考察在专属性、检测限和方法适用性等方面与中国药典无菌检查法是否存在差异。结果:在严格按照BC120全自动血培养系统使用说明操作的前提下,该系统在专属性和检测限参数上与药典方法无显著差异,多数情况下比药典方法更快地报告阳性结果。结论:BC120全自动血培养系统在风险管理的前提下,经过验证,可作为药典无菌检查的替代方法用于特定注射剂产品的生产过程控制和快速放行。Objective: To evaluate the feasibility of BC120 blood culture system as an alternative method for sterility test. Methods: Two aseptic preparations were collected, to examine the differences between them and pharmacopoeia method in specificity, detection limit and method applicability. Results: According to the instructions of BC120 blood culture system, there is no significant difference between the system and the pharmacopoeia method in specificity and detection limit parameters, and in most cases, the positive results are reported faster than the pharmacopoeia method. Conclusions: Under the premise of risk management, BC120 blood culture system can be used as an alternative method for sterile testing in the production process of specific injection products for sterile quality control and rapid release after validation.

miR-21低表达对垂体瘤细胞系RC-4BC增殖、凋亡的影响及与PTEN靶向关系

目的观察微小RNA-21(miR-21)低表达对垂体瘤细胞系RC-4BC增殖、凋亡的影响,并分析其与第10号染色体丢失的张力蛋白同源磷酸酶基因(PTEN)的靶向关系。方法取对数生长期的RC-4BC细胞分为两组,沉默组转染miR-21抑制物miR-21 inhibitor,阴性对照组转染抑制物阴性对照NC-inhibitor,采用RT-PCR法检测miR-21、第10号染色体丢失的张力蛋白同源磷酸酶基因(PTEN)mRNA,采用CCK8实验观察两组细胞增殖能力(以OD值表示),采用平板克隆实验观察两组细胞集落形成能力(以集落形成数表示),采用流式细胞术观察两组细胞凋亡率并观察细胞周期分布情况。收集RC-4BC细胞制备单细胞悬液,分别将miR-21 mimics或NC-mimics与PTEN-WT或PTEN-MUT共转染至RC-4BC细胞,转染后细胞标记为miR-21 mimics+PTEN-WT组、NC-mimics+PTEN-WT组、miR-21 mimics+PTEN-MUT组、NC-mimics+PTEN-MUT组,采用双荧光素酶报告基因实验验证miR-21与PTEN的靶向关系。结果沉默组RC-4BC细胞中miR-21、PTEN mRNA相对表达量分别为0.30±0.08、2.89±0.14,阴性对照组RC-4BC细胞中miR-21、PTEN mRNA相对表达量分别为1.01±0.02、0.99±0.03,两组相比,P均<0.05。沉默组RC-4BC细胞24 h、48 h、72 h时OD值均低于阴性对照组(P均<0.05)。沉默组RC-4BC细胞集落形成数低于阴性对照组(P<0.05)。沉默组RC-4BC细胞凋亡率高于阴性对照组(P<0.05)。沉默组RC-4BC细胞G0/G1期占比65.65%±7.82%、S期占比19.25%±3.70%,阴性对照组RC-4BC细胞G0/G1期占比45.62%±5.03%、S期占比35.72%±4.67%,两组相比,P均<0.05。miR-21 mimics+PTEN-WT组、NC-mimics+PTEN-WT组、miR-21 mimics+PTEN-MUT组、NC-mimics+PTEN-MUT组细胞的相对荧光素酶活性分别为0.39±0.07、1.02±0.03、1.01±0.04、1.00±0.03,其中miR-21 mimics+PTEN-WT组相对荧光素酶活性与其他各组相比,P均<0.05。结论沉默miR-21能够移至垂体瘤细胞系RC-4BC的增殖、促进其凋亡,其机制可能与靶向调控PTEN基因有关。

高压管汇中活动弯管BC直接头失效分析

高压管汇作为压裂设备核心部件之一,比泵头体、泵阀等易损件失效危害更大。为此,以失效活动弯管BC直接头为研究对象,采用硬度检测、金相检验、扫描电镜检测等手段分析了失效直接头材料力学性能和断口形貌,并利用有限元方法计算了直接头轴肩根部含初始缺陷处的应力强度。分析结果表明:BC直接头失效是由应力集中导致的脆性断裂而产生;应力集中、组装配合不当使其受力不均、材料硬度偏高和力学性能不达标,由此造成接头在循环载荷作用下发生脆性断裂;建议严格控制接头原材料复检及产品质量检验,规范产品结构组装标准,定量规范管汇安装标准。所得结论可为压裂高压管汇接头的失效分析提供理论参考。

D-CBCT在肺癌容积旋转调强计划精准治疗中的临床应用

目的探讨椎形束CT(D-CBCT)在肺癌容积旋转调强(VMAT)计划精准治疗中的临床应用。方法选取2019年10月~2022年10月在南通市第三人民医院放射治疗科就诊的100例肺癌患者。根据CBCT扫描模式不同,分为4D组(n=57)和3D组(n=43)。比较两组患者放疗摆位误差、内靶区(ITV)体积、靶区剂量、心脏受照剂量和肿瘤控制效果。结果在校正前后和治疗后,两组各摆位误差绝对值无统计学差异(P>0.05);4D组患者中下叶肿瘤ITV体积低于3D组(P<0.05);4D组的最大剂量(D_(max))、最小剂量(D_(min))和平均剂量(D_(mean))靶区剂量均高于3D组(P<0.05);4D组的V10、V20、V30及平均受量(D_(mean))等心脏受照剂量均低于3D组(P<0.05);4D组和3D组患者的客观有效率无明显差异(P>0.05)。结论可将D-CBCT应用于肺癌容积旋转调强计划精准治疗中,尤其采用4D-CBCT可更好提供靶区剂量,减少肺癌患者的中下叶肿瘤ITV体积和心脏受照剂量。

Revolutionizing gastric cancer treatment:The potential of immunotherapy

Gastric cancer,a prevalent malignancy worldwide,ranks sixth in terms of frequency and third in fatality,causing over a million new cases and 769000 annual deaths.Predominant in Eastern Europe and Eastern Asia,risk factors include family medical history,dietary habits,tobacco use,Helicobacter pylori,and Epstein-Barr virus infections.Unfortunately,gastric cancer is often diagnosed at an advanced stage,leading to a grim prognosis,with a 5-year overall survival rate below 5%.Surgical intervention,particularly with D2 Lymphadenectomy,is the mainstay for early-stage cases but offers limited success.For advanced cases,the National Comprehensive Cancer Network recommends chemotherapy,radiation,and targeted therapy.Emerging immunotherapy presents promise,especially for unresectable or metastatic cases,with strategies like immune checkpoint inhibitors,tumor vaccines,adoptive immunotherapy,and nonspecific immunomodulators.In this Editorial,with regards to the article“Advances and key focus areas in gastric cancer immunotherapy:A comprehensive scientometric and clinical trial review”,we address the advances in the field of immunotherapy in gastric cancer and its future prospects.

Pathologically successful conversion hepatectomy for advanced giant hepatocellular carcinoma after multidisciplinary therapy:A case report and review of literature

BACKGROUND Hepatocellular carcinoma(HCC)is one of the leading causes of death due to its complexity,heterogeneity,rapid metastasis and easy recurrence after surgical resection.We demonstrated that combination therapy with transcatheter arterial chemoembolization(TACE),hepatic arterial infusion chemotherapy(HAIC),Epclusa,Lenvatinib and Sintilimab is useful for patients with advanced HCC.CASE SUMMARY A 69-year-old man who was infected with hepatitis C virus(HCV)30 years previously was admitted to the hospital with abdominal pain.Enhanced computed tomography(CT)revealed a low-density mass in the right lobe of the liver,with a volume of 12.9 cm×9.4 cm×15 cm,and the mass exhibited a“fast-in/fast-out”pattern,with extensive filling defect areas in the right branch of the portal vein and an alpha-fetoprotein level as high as 657 ng/mL.Therefore,he was judged to have advanced HCC.During treatment,the patient received three months of Epclusa,three TACE treatments,two HAIC treatments,three courses of sintilimab,and twenty-one months of lenvatinib.In the third month of treatment,the patient developed severe side effects and had to stop immunotherapy,and the Lenvatinib dose had to be halved.Postoperative pathological diagnosis indicated a complete response.The patient recovered well after the operation,and no tumor recurrence was found.CONCLUSION Multidisciplinary conversion therapy for advanced enormous HCC caused by HCV infection has a significant effect.Individualized drug adjustments should be made during any treatment according to the patient's tolerance to treatment.

ABC情绪行为疗法对围绝经期维持性血液透析患者心理状况及自我管理能力的影响研究

目的探讨ABC情绪行为疗法对围绝经期维持性血液透析患者心理状态及自我管理能力的影响。方法选取在海口市3家附属医院血液透析中心进行透析治疗的围绝经期维持性血液透析患者(80例)作为研究对象,根据透析时间分为实验组和对照组,各40例,对照组实施常规护理,实验组在常规护理的基础上实施ABC情绪行为疗法,比较干预前后两组心理状态及自我管理能力。结果干预后,实验组心理状态及自我管理能力均优于对照组,差异有统计学意义。结论ABC情绪行为疗法可以改善围绝经期维持性血液透析患者焦虑、抑郁等负面情绪,同时提高其自我管理能力,是一种较为理想的心理干预措施,具有较高临床应用价值。

PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma:A case report

BACKGROUND Pancreatic ductal adenocarcinoma(PDAC)is a highly fatal disease with limited effective treatment especially after first-line chemotherapy.The human epidermal growth factor receptor 2(HER-2)immunohistochemistry(IHC)positive is associated with more aggressive clinical behavior and shorter overall survival in PDAC.CASE SUMMARY We present a case of multiple metastatic PDAC with IHC mismatch repair proficient but HER-2 IHC weakly positive at diagnosis that didn’t have tumor regression after first-line nab-paclitaxel plus gemcitabine and PD-1 inhibitor treatment.A novel combination therapy PRaG 3.0 of RC48(HER2-antibody-drug conjugate),radio-therapy,PD-1 inhibitor,granulocyte-macrophage colony-stimulating factor and interleukin-2 was then applied as second-line therapy and the patient had confirmed good partial response with progress-free-survival of 6.5 months and overall survival of 14.2 month.She had not developed any grade 2 or above treatment-related adverse events at any point.Percentage of peripheral CD8^(+) Temra and CD4^(+) Temra were increased during first two activation cycles of PRaG 3.0 treatment containing radiotherapy but deceased to the baseline during the maintenance cycles containing no radiotherapy.CONCLUSION PRaG 3.0 might be a novel strategy for HER2-positive metastatic PDAC patients who failed from previous first-line approach and even PD-1 immunotherapy but needs more data in prospective trials.

Immunotherapy for esophageal cancer:Where are we now and where can we go

Immune checkpoint inhibitor therapy has dramatically improved patient prognosis,and thereby transformed the treatment in various cancer types including esophageal squamous cell carcinoma(ESCC)in the past decade.Monoclonal antibodies that selectively inhibit programmed cell death-1(PD-1)activity has now become standard of care in the treatment of ESCC in metastatic settings,and has a high expectation to provide clinical benefit during perioperative period.Further,anti-cytotoxic T-lymphocyte–associated protein 4(CTLA-4)monoclonal antibody has also been approved in the treatment of recurrent/metastatic ESCC in combination with anti-PD-1 antibody.Well understanding of the existing evidence of immune-based treatments for ESCC,as well as recent clinical trials on various combinations with chemotherapy for different clinical settings including neoadjuvant,adjuvant,and metastatic diseases,may provide future prospects of ESCC treatment for better patient outcomes.

Back to the drawing board:Overview of the next generation of combination therapy for inflammatory bowel disease

Inflammatory bowel disease(IBD)is entering a potentially new era of combined therapeutics.Triantafillidis et al provide an insightful review of the current state of combination therapy,with a focus on the use of a combined biologic and immunomodulator,as well as emerging data on the future potential of dual-biologic therapy(DBT).While current evidence for DBT is limited,encouraging safety profiles and ongoing trials suggest a brighter future for this approach.The importance of controlled trials should be stressed in establishing new treatment paradigms.Ongoing prospective randomized trials of DBT and perhaps future combinations of biologics and small molecule therapies will hopefully guide the next generation of IBD care.

Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma

Hepatocellular carcinoma(HCC)is a high mortality neoplasm which usually appears on a cirrhotic liver.The therapeutic arsenal and subsequent prognostic outlook are intrinsically linked to the HCC stage at diagnosis.Notwithstanding the current deployment of treatments with curative intent(liver resection/local ablation and liver transplantation)in early and intermediate stages,a high rate of HCC recurrence persists,underscoring a pivotal clinical challenge.Emergent systemic therapies(ST),particularly immunotherapy,have demonstrate promising outcomes in terms of increase overall survival,but they are currently bound to the advanced stage of HCC.This review provides a comprehensive analysis of the literature,encompassing studies up to March 10,2024,evaluating the impact of novel ST in the early and intermediate HCC stages,specially focusing on the findings of neoadjuvant and adjuvant regimens,aimed at increasing significantly overall survival and recurrence-free survival after a treatment with curative intent.We also investigate the potential role of ST in enhancing the downstaging rate for the intermediate-stage HCC initially deemed ineligible for treatment with curative intent.Finally,we critically discuss about the current relevance of the results of these studies and the encouraging future implications of ST in the treatment schedules of early and intermediate HCC stages.

Adjuvant therapy for hepatocellular carcinoma:Dilemmas at the start of a new era

Approximately 50%-70%of patients with hepatocellular carcinoma experience recurrence within five years after curative hepatic resection or ablation.As a result,many patients receive adjuvant therapy after curative resection or ablation in order to prolong recurrence-free survival.The therapy recommended by national guidelines can differ,and guidelines do not specify when to initiate adjuvant therapy or how long to continue it.These and other unanswered questions around adjuvant therapies make it difficult to optimize them and determine which may be more appropriate for a given type of patient.These questions need to be addressed by clinicians and researchers.

Vonoprazan-amoxicillin dual regimen with Saccharomyces boulardii as a rescue therapy for Helicobacter pylori:Current perspectives and implications

Yu et al’s study in the World Journal of Gastroenterology(2023)introduced a novel regimen of Vonoprazan-amoxicillin dual therapy combined with Saccharomyces boulardii(S.boulardii)for the rescue therapy against Helicobacter pylori(H.pylori),a pathogen responsible for peptic ulcers and gastric cancer.Vonoprazan is a potassium-competitive acid blocker renowned for its rapid and long-lasting acid suppression,which is minimally affected by mealtime.Compared to proton pump inhibitors,which bind irreversibly to cysteine residues in the H+/K+-ATPase pump,Vonoprazan competes with the K+ions,prevents the ions from binding to the pump and blocks acid secretion.Concerns with increasing antibiotic resistance,effects on the gut microbiota,patient compliance,and side effects have led to the advent of a dual regimen for H.pylori.Previous studies suggested that S.boulardii plays a role in stabilizing the gut barrier which improves H.pylori eradication rate.With an acceptable safety profile,the dual-adjunct regimen was effective regardless of prior treatment failure and antibiotic resistance profile,thereby strengthening the applicability in clinical settings.Nonetheless,S.boulardii comes in various formulations and dosages,warranting further exploration into the optimal dosage for supplementation in rescue therapy.Additionally,larger,randomized,double-blinded controlled trials are warranted to confirm these promising results.

Early antiplatelet therapy used for acute ischemic stroke and intracranial hemorrhage

In this editorial we comment on the article published by Zhang et al in the recent issue of World Journal of Clinical Cases.We evaluate their claims on the benefit of use of Aspirin in the early management of patients with ischemic stroke.We also comment on their contention of using aspirin in the early management of patients with intracranial hemorrhage,a practice not seen in modern medicine.Large clinical trials such as the International Stroke Trial and the Chinese Acute Stroke Trial have shown the benefit of Aspirin use within 48 h of patients with Acute Ischemic Stroke.The findings were corroborated in the open-label trial performed by Zhang et al in a smaller sample group of 25 patients where they showed improvement in functional scores at 90 days without an increase in adverse events.As such,this intervention is also recommended by the American Heart Association stroke guidelines from 2021.With regard to Intracranial hemorrhage,traditional practice has been to discontinue or avoid antiplatelet therapy in these patient groups.However,no studies have been done to evaluate this management strategy that is more borne out of the mechanism behind Aspirin’s effect on the coagulation pathway.Zhang et al evaluate the benefits of Aspirin on patients with low-volume intracranial hemorrhage,i.e.,less than 30 mL on computed tomo-graphy imaging,and show no increase in mortality.The caveat of this finding is that all outcomes were pooled into one group for results,and the number of patients was low.While more studies with larger patient groups are required,the data from Zhang et al suggests that patients with small-volume intracranial hemorrhages may benefit from Aspirin administration in the acute phase of management.

Effects of hormone replacement therapy on mood and sleep quality in menopausal women

BACKGROUND Hormone replacement therapy is an effective treatment strategy for the management of symptoms in naturally menopausal women.However,some patients report experiencing adverse effects.AIM To analyze the effects of hormone replacement therapy in menopausal female patients.METHODS A total of 152 menopausal female patients admitted to the Gynecology Department of the Ganzhou Maternal and Child Health Hospital between January 2021 and December 2023 were divided into the observation group(n=76,conventional treatment+hormone replacement therapy)and the control group(n=76,conventional treatment only)via random casting.The improvement observed in the following items were compared between the groups:Kupperman menopausal index(KMI),emotional state[The Positive and Negative Affect Scale(PANAS)],sleep quality[Self-Rating Scale of Sleep(SRSS)],treatment effectiveness,and treatment safety.RESULTS The modified KMI and SRSS scores of the observation group were lower than those of the control group after three rounds of treatment.The improvement in the PANAS score observed in the observation group was greater than that observed in the control group(P<0.05).The total treatment effectivity rate in the observation group was higher than that in the control group(86.84%vs 96.05%,χ2=4.121,P=0.042).The incidence rate of adverse reactions in the two groups was comparable(6.58%vs 9.21%,χ2=0.361,P=0.547).CONCLUSION Hormone replacement therapy effectively improved the clinical symptoms,actively channeled negative emotions,and improved the quality of sleep in menopausal patients,indicating its effectiveness and safety.